Clinicopathologic Features of V600E and V600K Melanoma—Response
نویسندگان
چکیده
منابع مشابه
Clinicopathologic features of V600E and V600K melanoma--letter.
The presence of a BRAF mutation in a melanoma tumor predicts response to BRAF inhibitors; however, the biological characteristics of tumors with different BRAFmutations have not been investigated until recently. Menzies and colleagues reported that the rarer V600K BRAF mutations were found more commonly in metastatic tumors of patients who were older at diagnosis, had evidence of chronic sun da...
متن کاملDistinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma.
PURPOSE Certain clinicopathologic features correlate with BRAF mutation status in melanoma including younger age and primary subtype. This study sought to determine the BRAF mutation status by age-decade and whether BRAF-mutant genotypes correlated with clinicopathologic features and outcome in patients with metastatic melanoma. METHODS A prospectively assembled cohort of Australian patients ...
متن کاملHuman Cancer Biology Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma
Purpose:Certain clinicopathologic features correlate with BRAFmutation status inmelanoma including younger age and primary subtype. This study sought to determine the BRAFmutation status by age-decade and whether BRAF-mutant genotypes correlated with clinicopathologic features and outcome in patients with metastatic melanoma. Methods: A prospectively assembled cohort of Australian patients were...
متن کاملCorrelation between the BRAF V600E mutation status and the clinicopathologic features of papillary thyroid carcinoma.
This study sought to investigate the correlations of V-raf murine sarcoma viral oncogene homolog B1 (BRAF) gene mutations with the clinicopathologic features of papillary thyroid carcinoma and central lymph node metastasis. We retrospectively analyzed the 2-year medical records of patients who underwent surgery for papillary thyroid carcinoma. After screening, the records of 126 patients who me...
متن کاملThe safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma.
INTRODUCTION In the recent years, melanoma patients' outcome and survival improved, mainly because of systemic treatment improvement with targeted therapy and checkpoint blockade. Targeted therapy with BRAF and MEK inhibitors was approved to treat patients with unresectable or metastatic melanoma, harboring BRAF V600 mutations. This paper addresses the safety and efficacy of cobimetinib, when u...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Cancer Research
سال: 2012
ISSN: 1078-0432,1557-3265
DOI: 10.1158/1078-0432.ccr-12-3054